The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Osteogenics Biomedical sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Osteogenics Biomedical is a medical equipment company that develops bone grafting products. The company’s product portfolio includes collagen membranes, dPTFE membranes, ridge augmentation mesh, allograft bone substitutes, xenograft bone substitutes, alloplast (synthetic) bone substitutes, collagen wound dressings, absorbable sutures, non-absorbable sutures, ridge preservation kits, fixation and tenting systems, bone harvesting instruments, instruments and surgical textbooks. The company offers its products under the brands, enCore, Zcore, Cytoplast, Vitala, Zmatrix, NovaBone and others. The company distributes its products worldwide. Osteogenics Biomedical is headquartered in Lubbock, Texas, the US.
The key metrics of Osteogenics Biomedical related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Osteogenics Biomedical is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Osteogenics Biomedical.
For a detailed understanding of the performance of Osteogenics Biomedical, buy the report here.